title: Serotonin syndrome caused by interaction between citalopram and fentanyl.
abstract: OBJECTIVE
  To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.
  
  
  METHODS
  A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl.
  
  
  CONCLUSIONS
  Serotonin syndrome is a potentially lethal pharmacodynamic interaction between medications that increase serotonergic transmission at the synaptic junction. The development of new pharmacological agents with varied properties and actions has increased the risk of serotonin syndrome as a clinical diagnosis. SSRIs and fentanyl are commonly co-administered, especially in the setting of chronic or malignant pain, as underlying depression may contribute to the pathogenesis of pain.
  
  
  CONCLUSIONS
  Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs.
authors: Department of Medicine, State University of New York, Buffalo, NY, USA.
authors: S
authors: S
authors: Ailawadhi
authors: K-W
authors: KW
authors: Sung
authors: L A
authors: LA
authors: Carlson
authors: M R
authors: MR
authors: Baer
mesh_terms: D000368:Aged; D015283:Citalopram / Q000009:adverse effects* / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005283:Fentanyl / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D009196:Myeloproliferative Disorders / Q000188:drug therapy; D020230:Serotonin Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D015283:Citalopram; D005283:Fentanyl; D017367:Selective Serotonin Reuptake Inhibitors